{
  "id": "carcinoma-in-situ",
  "title": "Carcinoma in situ",
  "lang": "en",
  "source_lang": "en",
  "summary": "Carcinoma in situ is an epithelial neoplasm confined to its tissue of origin, without invasion into underlying supporting tissue.",
  "category": "health",
  "subcategory": "diseases",
  "type": "concept",
  "aliases": [
    "CIS",
    "In situ carcinoma",
    "Noninvasive carcinoma"
  ],
  "generated_at": "2026-11-06",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/carcinoma-in-situ/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/carcinoma-in-situ/",
      "json": "https://aiwiki.page/zh/carcinoma-in-situ.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "Carcinoma in situ (CIS) is a neoplastic lesion in which abnormal epithelial cells have features associated with carcinoma but remain confined to the epithelium in which they arose, without invading underlying supporting tissue. The Latin phrase in situ means “in its original place.” Depending on the organ and classification system, CIS may be described as noninvasive cancer, stage 0 cancer, or a preinvasive lesion. These terms do not mean that progression to invasive cancer is inevitable."
    },
    {
      "heading": "Pathological definition",
      "text": "The defining distinction between carcinoma in situ and invasive carcinoma is the relationship of abnormal cells to the basement membrane, a specialized extracellular layer separating the epithelium from underlying connective tissue. In CIS, the abnormal cells have not crossed this boundary. Once they invade the supporting tissue, the lesion is classified as invasive carcinoma, even if the invasive component is very small.\n\nOn microscopic examination, CIS may show enlarged and irregular nuclei, increased cell division, and disorganization of the normal epithelial architecture. In stratified squamous epithelium, abnormal cells may extend through the full epithelial thickness. This description does not apply in the same way to glandular or ductal lesions, where abnormal cells occupy glands or ducts without invading the surrounding tissue.\n\nCarcinoma in situ overlaps with the terminology of severe dysplasia and high-grade intraepithelial neoplasia. The relationship among these categories depends on the organ and the classification in use; they are not universally interchangeable.\n\nA purely in situ lesion does not produce metastases. Metastatic spread requires an invasive component. When metastatic disease is found alongside a diagnosis of CIS, an important possibility is an invasive focus that was not represented in the original tissue sample."
    },
    {
      "heading": "Major forms",
      "text": "Carcinoma in situ is not a single disease with a uniform clinical course. Its biological significance and management vary substantially by anatomical site.\n\nSite or lesion | Principal characteristics\n**[[ductal-carcinoma-in-situ | Ductal carcinoma in situ]] of the breast**\nSquamous carcinoma in situ of the cervix | In contemporary terminology, this generally falls within high-grade squamous intraepithelial lesions, particularly cervical intraepithelial neoplasia grade 3. Persistent high-risk [[human-papillomavirus-infection\nAdenocarcinoma in situ of the cervix | A preinvasive glandular lesion distinct from squamous intraepithelial disease. Its distribution within the cervical canal can complicate assessment of its extent.\nUrothelial carcinoma in situ | A flat, high-grade lesion of the urinary tract lining, especially the bladder. Although noninvasive, it has clinically important potential to progress to invasive disease.\nSquamous cell carcinoma in situ of the skin | Often called Bowen disease. Abnormal squamous cells remain within the epidermis; invasion into the dermis changes the diagnosis to invasive squamous cell carcinoma.\n\nSome similarly named lesions require separate interpretation. Classical lobular carcinoma in situ of the breast is generally regarded as both a marker of increased future breast cancer risk and a non-obligate precursor. It is not staged or managed in the same way as ductal carcinoma in situ. More atypical lobular variants have different implications.\n\nMelanoma in situ also describes disease confined to its tissue of origin, but melanoma arises from melanocytes rather than epithelial cells and is not a carcinoma."
    },
    {
      "heading": "Detection and diagnosis",
      "text": "Many in situ lesions cause no symptoms and are found through cancer screening or investigations undertaken for another reason. Others produce site-specific findings, such as a persistent skin lesion or blood in the urine.\n\nDefinitive diagnosis generally depends on histopathological examination of tissue obtained by biopsy or excision. Imaging and cytology can identify suspicious abnormalities, but they do not always establish whether invasion is present.\n\nPathological assessment addresses several distinct questions:\n\n- Whether the lesion meets the criteria for an in situ neoplasm.\n- Whether any invasive component is present.\n- Its grade, extent, and other site-specific features.\n- Whether an excised lesion reaches the specimen margins.\n\nSampling is an important limitation. A small biopsy may identify CIS while missing an adjacent invasive focus. Consequently, examination of a larger excision specimen can change the diagnosis from in situ to invasive disease. This does not necessarily mean that progression occurred between the two procedures."
    },
    {
      "heading": "Staging and natural history",
      "text": "In many cancer staging systems, carcinoma in situ is designated Tis and may be grouped as stage 0. This convention is not universal: staging rules differ between organs, and some lesions with “in situ” in their names are handled separately.\n\nStage and grade describe different properties. Stage concerns anatomical extent, whereas grade describes microscopic characteristics associated with biological behavior. An in situ lesion can therefore be high grade while remaining noninvasive.\n\nThe course of untreated CIS varies by site and subtype. Some lesions progress to invasive cancer, whereas others remain noninvasive for long periods. The likelihood and timing of progression cannot be represented by a single percentage applicable to all CIS.\n\nNatural-history estimates are also difficult to establish because many lesions are treated after detection. Studies of untreated lesions may involve selected populations, incomplete sampling, or historical diagnostic criteria."
    },
    {
      "heading": "Management and clinical significance",
      "text": "Management is site-specific rather than determined by the label “carcinoma in situ” alone. Established approaches can include local excision, other forms of surgery, radiation therapy, and organ-specific local treatments. For example, bladder CIS may be treated with intravesical bacillus Calmette–Guérin, an immune-based treatment delivered into the bladder. Selected breast lesions may also involve endocrine treatment.\n\nAssessment commonly incorporates lesion extent, grade, completeness of removal, the possibility of unsampled invasion, and individual clinical factors. Follow-up methods likewise depend on the affected organ.\n\nDetection of CIS can enable treatment before invasion develops, but it also raises the issue of overdiagnosis: identifying a lesion that would never have caused symptoms or harm during the person's lifetime. Distinguishing lesions that require intervention from those suitable for less intensive management remains an important subject of clinical trials, particularly in selected low-risk ductal carcinoma in situ of the breast."
    }
  ],
  "links": [
    "carcinoma",
    "cancer",
    "metastasis",
    "breast-cancer",
    "human-papillomavirus-infection",
    "melanoma",
    "cancer-screening",
    "diagnosis",
    "histopathology",
    "biopsy",
    "cancer-staging",
    "surgery",
    "radiation-therapy",
    "overdiagnosis",
    "clinical-trial"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}